E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Adult individuals with bipolar I disorders who initiate lithium treatment
based on the decision of themselves and their clinician |
|
E.1.1.1 | Medical condition in easily understood language |
Adult individuals with bipolar I disorders who initiate lithium treatment
based on the decision of themselves and their clinician |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Mental Disorders [F03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10057667 |
E.1.2 | Term | Bipolar disorder |
E.1.2 | System Organ Class | 10037175 - Psychiatric disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective of this study is to identify the eligibility criteria for
treatment with Li in BDI in terms of response, safety and tolerability
Primary Objective: To evaluate the predictive values of the biomarkers
collected during the first three months of Lithium treatment on long term
Lithium response (2 years) define according the primary outcome
measures |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the prognostic values of the biomarkers collected during the
first three months of Lithium treatment on long term Lithium response
(2 years) define according the secondary outcome measures |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Decision to prescribe Li as a prophylactic treatment based on
clinicians' assessment
2. Confirmed diagnosis of BD1 according to DSM-5 criteria [based on
the Mood section of the SCID]
3. Aged 18-70 years.
4. Able and willing to give written informed consent
5. Eligible for, and consents to blood sample for the purpose of the
RLiNK study
6. Covered by a Social Security Insurance where applicable |
|
E.4 | Principal exclusion criteria |
1 Trial of Lithium undertaken within the last 6 months
2 Lifetime history of mood disorder better explained by a DSM-5
definition for schizoaffective disorder [based on the relevant section of
the SCID]
3 Pre-lithium screening suggest that Lithium initiation is
contraindicated:
4 Participation in another research protocol that interferes with the
evaluation of Lithium response (efficacy or tolerance)
5 Severe risk of self-harm at present, based on clinician's evaluation
6 Protected adult |
|
E.5 End points |
E.5.1 | Primary end point(s) |
After all study participants have completed the follow-up period, the
expert panel will reach a consensus on the classification of each
participant into one of three categories: (i) good responders (GR), (ii)
partial responders (PR), (iii) non-responders (NR). If no clinical followup
data are available, the participant will be categorized as
unclassifiable (UC). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After all study participants have completed the follow-up period, the
expert panel will reach a consensus on the classification of each
participant into one of three categories: (i) good responders (GR), (ii)
partial responders (PR), (iii) non-responders (NR). If no clinical followup
data are available, the participant will be categorized as
unclassifiable (UC). |
|
E.5.2 | Secondary end point(s) |
There are several possible definitions of treatment response that employ
different levels of precision.
a) Response assessed retrospectively by estimating the total score
b) Time dependent measures of outcome
c) Continuous ratings of BD symptoms |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The durations of the clinician-rated and self-questionnaires at each visit
are detailed in Table 3 of the protocole
- Definition of a Missing face to face visit: Planned appointment +
1month
- Definition of a Missing telephone visit: Planned appointment + 1 week
- In case of missing visit the information needed to inform the primary
outcome (such as relapse, hospitalisation, suicide attempt,
comorbidities…) will be collected retrospectively at the next visit. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 16 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last follow-up visit of the last patient |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 36 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 36 |